Contract developer Minnetronix Medical recent Announce It has developed and commercialized its own product, a scalable deep-brain access port called eyes of the mind.
The São Paulo-based company was founded in 1996. During these 26 years, Minnetronix has manufactured devices covering four key technology areas: optical systems, radio frequency energy, stimulation and active wearables, and fluid and gas management. Matt Adams, general manager of Minnetronix, said in an interview that the company has the expertise to develop products in most areas of medicine — from neurology to cardiology to gastroenterology to critical care.
By now, Minnetronix is known for developing products for other companies.Some of these include Medtronic, Abbott, combination therapy, Boston Scientific and Minerva Surgery.
In the past, these companies and others would come to Minnesota with product ideas and conduct research and development on their behalf. Now, companies can still do this, but they can also come to Minnetronix for a fully finished product – conceived, designed, developed, manufactured and passed regulatory clearance.
“As far as MindsEye is concerned, if you’re a company with a sales force that’s focused on the neuro area, our product is completely done,” Adams said. “We can put it right into your sales package and will continue to work together to manufacture and improve it over time.”
This is what is happening MindsEye Partners of Minnetronix— Mizuho USA – This will distribute the device across the US
Some forms of stroke and cancer cause lesions deep in the brain, and removing them can be a very invasive and dangerous process. Adams claims MindsEye is the only scalable, minimally invasive deep-brain access port on the market. Thus, it addresses an unmet need in the neurology market.
The port provides deep brain access and visualization during surgery to treat stroke and cancer. Adams claims it is “much less damaging” to the brain than the more invasive ports previously offered by companies like Medtronic and Boston Scientific.
eyes of the mind made money It was approved by the Food and Drug Administration in 2020 and can be reimbursed.Its first live human use case is in Tulane Medical Center Neurosurgeons Dr. Art Wang and Dr. Johnny Delashaw. Tulane now routinely uses the device in its neurosurgery department.
Adams claimed that after developing MindsEye, Minnetronix could take its future partnerships “to a whole new level” as equipment companies now have the option of getting the finished product.company There are plans to continue to conceive and develop more products in-house in the future.
The next in-house product in Minnetronix’s portfolio is Neurapheresis, which Adams describes as “a very novel system that’s essentially like dialysis of your cerebrospinal fluid.” The company recently completed two forward-looking, A multicenter U.S. clinical trial, Adams said Minnetronix is currently looking for a partner to distribute the device.
Image credit: Minnett Medical
